Our Approach

Accelerating Drug Discovery and Development

The world’s greatest scientific achievements were made when people decided to work together. Landing on the moon, finding a vaccine for smallpox and creating effective therapies to treat HIV/AIDs, all resulted from big thinking and innovative collaboration on a grand scale.

In 2013, Target ALS set out to build the ALS Innovation Ecosystem to break down the barriers to progress and bring together the right people and resources to accelerate drug discovery and development.


The Innovation Ecosystem includes six critical components

Collaborative Funding

Target ALS  fosters collaboration by exclusively funding multi-investigator research consortia that pursue novel approaches in ALS drug discovery and development.

Scientific Tools and Resources

ALS researchers worldwide have access to a range of critical tools ranging from biospecimens to genomic datasets to stem cells with no strings attached.

Industry Engagement

Target ALS offers the pharma/biotech industry access to its funding and resources to promote collaborative research projects across academia and industry and to seed ALS drug discovery programs in the industry. By fostering partnerships, we are accelerating progress toward effective treatments for ALS.

Independent Grant Review

All funding decisions are reviewed and ultimately decided by a conflict-free Independent Review Committee.

No Intellectual Property Restrictions

To further foster collaboration and encourage the free flow of information, Target ALS has no intellectual property (IP) restrictions on data generated by its funded research projects or through use of its scientific tools and resources.

Networking and Communication

Target ALS fosters ongoing networking and communication and hosts a range of scientific meetings. During our annual scientific meeting in Cambridge, Mass., scientists, foundations, venture capitalists, industry leaders and donors convene to coordinate, communicate and collaborate around leading research ideas.


Join Us to Change the Prognosis for Patients

In just a few years time, the Target ALS Innovation Ecosystem has produced the first therapeutic options with a strong biologic rationale. For the first time in the 150 year history of the disease, we face a historic opportunity to radically change the prognosis for patients.

Over the next several years and with your support, Target ALS will expand the ALS Innovation Ecosystem to effectively drive the development of new therapies and their rapid translation into the clinic. Learn more about our new plan to produce the first set of transformative breakthroughs on behalf of patients. 

Together, we can achieve historic breakthroughs and change the prognosis for patients.

We invite you to join us.